97275 ⎘
Immunoglobulins specific features characterized by immunoglobulin fragments; Constant or Fc region; Isotype CH1 domain
PH-DEPENDENT ANTI-CD3 ANTIBODIES AND METHODS RELATING THERETO
#2ENGINEERED NON-HUMAN ANIMALS
#3MULTISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD22 AND 4-1BB AND METHODS OF USE THEREOF
#4CDCP1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
#5TRISPECIFIC ANTIBODIES TARGETING PD-1, CTLA-4 AND VEGF AND USE THEREOF
#6MESOTHELIN-TARGETED CD40 AGONISTIC MULTISPECIFIC ANTIBODY CONSTRUCTS FOR THE TREATMENT OF SOLID TUMORS
#7Cµ4 REGION FOR PAIRING HEAVY AND LIGHT CHAINS IN MULTI-SPECIFIC ANTIBODIES
#8FUSIONS WITH CD8 ANTIGEN BINDING MOLECULES FOR TREATING CHRONIC VIRAL INFECTION
#9METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION
#10MULTIVALENT FZD4, WNT CO-RECEPTOR, AND VEGF BINDING MOLECULES AND USES THEREOF
#11TREATMENT OF CANCER USING AN ANTI-HLA-G/ANTI-CD3 BISPECIFIC ANTIBODY AND A 4-1BB (CD137) AGONIST
#12TRANSGENIC NON-HUMAN ANIMALS PRODUCING MODIFIED HEAVY CHAIN-ONLY ANTIBODIES
#13ANTI-GPRC5D ANTIBODY AND USE THEREOF
#14ALL-IN-ONE AGONISTIC ANTIBODIES
#15EQUINE ANTIBODY MUTANTS
#16ANTIGEN BINDING MOLECULES TO CD3 AND CD19
#17ANTIBODIES TARGETING C-KIT AND/OR SIGLEC AND USES THEREOF
#18Engineered Heterodimeric Proteins
#19BISPECIFIC ANTIBODY AND APPLICATION THEREOF
#20TETRAVALENT MULTISPECIFIC ANTIBODIES
#21COMBINATION THERAPY WITH ANTI-PVRIG ANTIBODIES FORMULATIONS AND ANTI-PD-1 ANTIBODIES
#22ANTI-ETEC ADHESIN PROTEIN ANTIBODIES AND METHODS OF USE
#23MODIFIED ANTIBODIES AND USES THEREOF
#24RNA COMPOSITIONS TARGETING HIV
#25RECOMBINANT BINDING PROTEINS WITH ACTIVATABLE EFFECTOR DOMAIN
#26NOVEL METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEX
#27EPCAM-CD3 EPSILON BISPECIFIC ANTIBODIES
#28BINDING PROTEINS COMPRISING AN ANTI-IMMUNE CHECKPOINT ANTIBODY OR A FRAGMENT THEREOF AND SINGLE-CHAIN TNFRSF LIGAND MULTIMERS
#29ANTI-TNF-ALPHA ANTIBODIES AND COMPOSITIONS
#30ANTI-TIGIT AND ANTI-PVRIG IN MONOTHERAPY AND COMBINATION TREATMENTS
#31ANTI-PCRV AND PSL BISPECIFIC ANTIBODIES FOR TREATMENT OF BRONCHIECTASIS
#32METHODS OF TREATING CANCER USING TRISPECIFIC BINDING PROTEINS TARGETING HER2-EXPRESSING TUMORS
#33MULTISPECIFIC ANTI-CD40 / ANTI-FAP ANTIBODIES AND USES THEREOF
#34COMPOSITIONS AND METHODS RELATED TO RECEPTOR PAIRINGS
#35METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEX
#36METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES
#37METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES
#38MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND RELATED METHODS AND USES
#39ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF
#40ANTIGEN-BINDING PROTEINS AND RELATED METHODS OF USE
#41ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#42ANTIBODIES WITH ENGINEERED CH2 DOMAINS, COMPOSITIONS THEREOF AND METHODS OF USING THE SAME
#43COMPOSITIONS AND METHODS RELATED TO RECEPTOR PAIRINGS
#44METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES
#45ANTI-CD28 ANTIBODIES
#46CLDN18.2-TARGETING ANTIBODY, BISPECIFIC ANTIBODY AND USE THEREOF
#47TETRAVALENT BISPECIFIC AND TETRASPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
#48ACTIVATABLE ANTIGEN-BINDING PROTEIN CONSTRUCTS AND USES OF THE SAME
#49IL10RB BINDING MOLECULES AND ENCODING NUCLEIC ACIDS
#50ANTIGEN BINDING MOLECULE FORMATS
#51HEAVY CHAIN ONLY ANTIBODIES TO PDGF
#52MULTISPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
#53HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
#54BISPECIFIC ANTI-HUMAN A-BETA/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
#55IL-18BP ANTAGONIST ANTIBODIES AND THEIR USE IN MONOTHERAPY AND COMBINATION THERAPY IN THE TREATMENT OF CANCER
#56Masked Multispecific Antigen-Binding Molecules with Cleavable Linkers
#57NOVEL ANTIGEN BINDING MOLECULE FORMATS
#58EXPRESSION TECHNOLOGY FOR ANTIBODY CONSTRUCTS
#59BISPECIFIC ANTIBODY
#60ANTIBODIES AND BISPECIFIC BINDING PROTEINS THAT BIND OX40 AND/OR PD-L1
#61BI- OR MULTI-SPECIFIC ANTIBODY
#62ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#63ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#64TRISPECIFIC BINDING PROTEINS, METHODS, AND USES THEREOF
#65TRISPECIFIC BINDING PROTEINS, METHODS, AND USES THEREOF
#66BISPECIFIC ANTIBODIES THAT BIND TO NKP46 AND MICA/B
#67ANTIGEN-BINDING PROTEIN COMPRISING TWO FC DOMAINS AND USE THEREOF
#68TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRBeta ANTIBODY
#69ANTI-CD39 NANOBODY AND USES THEREOF
#70BISPECIFIC ANTI-HUMAN A-BETA/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
#71CD19 BINDING MOLECULES AND USES THEREOF
#72ANTIGEN BINDING CONSTRUCTS TARGETING HER2 AND USES THEREOF
#73MODIFIED ANTIGEN BINDINGPOLYPEPTIDE CONSTRUCTS AND USES THEREOF
#74ANTI-HER2/ANTI-CD47 MOLECULES AND USES THEREOF
#75MULTISPECIFIC NK ENGAGER PROTEIN
#76ILT3 AND CD3 BINDING AGENTS AND METHODS OF USE THEREOF
#77ANTI-ETEC ADHESIN PROTEIN ANTIBODIES AND METHODS OF USE
#78NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND BCMA VARIANTS WITH FC-ENGINEERING
#79Novel formats of anti-CD28/sPD-1 fusion constructs
#80BISPECIFIC ANTIBODY FUSION MOLECULES AND METHODS OF USE THEREOF
#81IL-21 POLYPEPTIDES AND TARGETED CONSTRUCTS
#82Anti-ED-A Antibodies for the Treatment of Pulmonary Hypertension
#83Antigen Binding Polypeptides, Antigen Binding Polypeptide Complexes and Methods of Use Thereof in HIV
#84PH-SELECTIVE ANTIBODY FC DOMAINS
#85MULTISPECIFIC ANTIBODIES AND USES THEREOF
#86COMPOSITIONS AND METHODS RELATED TO IL27 RECEPTOR BINDING
#87MODIFIED-IgG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY
#88METHODS FOR PURIFYING BISPECIFIC ANTIBODIES
#89MULTISPECIFIC ANTIGEN-BINDING PROTEINS
#90IL27RAlpha BINDING MOLECULES AND METHODS OF USE
#91N-TERMINAL scFv MULTISPECIFIC BINDING MOLECULES
#92MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D, AND CD16, AND METHODS OF USE
#93BISPECIFIC ANTIBODY AND APPLICATION THEREOF
#94ANTI-B7-H4 ANTIBODY, AND PREPARATION METHOD THEREFOR AND USE THEREOF
#95DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES
#96T CELL ENGAGER MOLECULES AND USES THEREOF
#97ANTIBODY OPTIMIZATION
#98HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
#99HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CD38
#100ACTIVATABLE BISPECIFIC ANTI-CD3 AND ANTI-PD-L1 PROTEINS AND USES THEREOF
#101NOVEL ANTIGEN BINDING MOLECULE FORMATS
#102METHOD FOR PRODUCING AN ANTIBODY PEPTIDE CONJUGATE
#103ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER
#104ANTI-MET FAB-FC FOR THE TREATMENT OF A TUMOR AND/OR METASTASIS
#105IGG FC VARIANTS FOR VETERINARY USE
#106METHODS OF USING BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
#107FC-GAMMA RECEPTOR II BINDING AND GLYCAN CONTENT
#108ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES
#109IMMUNOMODULATORY FUSION PROTEINS
#110SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING
#111HER2-TARGETING ANTIGEN BINDING MOLECULES COMPRISING 4-1BBL
#112AGONISTIC CD28 ANTIGEN BINDING MOLECULES TARGETING HER2
#113STEAP2 DIRECTED T-CELL ENGAGERS AND COMPOSITIONS THEREOF
#114MONOSPECIFIC AND BISPECIFIC ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF
#115IL-21 POLYPEPTIDES AND TARGETED CONSTRUCTS
#116MULTISPECIFIC ANTIGEN-BINDING PROTEINS
#117TRIVALENT TRISPECIFIC ANTIBODY CONSTRUCTS
#118ANTI-TGFbeta ANTIBODY AND PREPARATION METHOD AND APPLICATION THEREOF
#119HER3 ANTIGEN-BINDING MOLECULES
#120Engineered Antibodies
#121OPTIMIZED NUCLEIC ACID ANTIBODY CONSTRUCTS
#122SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
#123AGENTS ENCODING CLDN6 AND CD3 BINDING ELEMENTS FOR TREATING CLDN6-POSITIVE CANCERS
#124IGA FC AND IGG FC TANDEM PROTEIN CONSTRUCTS
#125MULTISPECIFIC ANTIBODIES BINDING TO CD20, NKP46, CD16 AND CONJUGATED TO IL-2
#126DUAL MHC-TARGETING T CELL ENGAGER
#127NOVEL PD-1 BINDING DOMAINS
#128NOVEL PD-1 BINDING DOMAINS
#129ANTI-ANG2 ANTIBODY, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
#130Trispecific Engineered Antibodies
#131ANTI-TSHR MULTI-SPECIFIC ANTIBODIES AND USES THEREOF
#132MONOVALENT ASYMMETRIC TANDEM FAB BISPECIFIC ANTIBODIES
#133MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION WITH ANTI PD-1 ANTIBODIES FOR TREATING CANCERS
#134IgG EPITOPE AND APPLICATIONS THEREOF AS A DRUG TARGET
#135USES OF DLL3-TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULES
#136MULTISPECIFIC ANTIBODIES AND USES THEREOF
#137CAIX TARGETING IL-12 FUSION PROTEINS AND METHODS OF USE THEREOF
#138ANTIGEN-BINDING MOLECULE
#139MULTISPECIFIC PROTEINS BINDING TO NKP46, A CYTOKINE RECEPTOR, A TUMOUR ANTIGEN AND CD16A
#140ANTI-ETEC ADHESIN PROTEIN ANTIBODIES AND METHODS OF USE
#141IL23R BINDING MOLECULES AND METHODS OF USE
#142PROTEIN SPECIFICALLY BINDING TO PD-1 AND PHARMACEUTICAL USE THEREOF
#143AGONISTIC CD28 ANTIGEN BINDING MOLECULES TARGETING EPCAM
#144HETERODIMERIC PROTEINS
#145ORTHOGONAL MULTIMERIC PROTEINS
#146MULTIVALENT ANTIBODY
#147BISPECIFIC ANTI-CCL2 ANTIBODIES
#148MULTIVALENT ANTIBODY
#149MULTISPECIFIC ANTIGEN-BINDING PROTEIN AND USE THEREOF
#150METHODS AND COMPOSITIONS FOR TREATING CANCER
#151BISPECIFIC ANTI-HUMAN CD20/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
#152ANTI-CD3 ANTIBODIES
#153CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF
#154NOVEL MULTISPECIFIC ANTIBODIES
#155TAU-SPECIFIC ANTIBODY GENE THERAPY COMPOSITIONS, METHODS AND USES THEREOF
#156PD-1 ANTIBODIES, POLYPEPTIDES AND USES THEREOF
#157NOVEL ANTIGEN BINDING MOLECULE FORMATS
#158NOVEL ANTIBODY FORMAT
#159CHIMERIC IMMUNOGLOBULIN
#160MITIGATION OF THERAPEUTIC PROTEIN FRAGMENTATION DURING CELL CULTURE HARVEST PROCESSES
#161TRISPECIFIC ANTIBODY AND PREPARATION METHOD THEREFOR AND USE THEREOF
#162ENGINEERED NON-HUMAN ANIMALS FOR PRODUCING ANTIBODIES
#163VARIANT CH1 DOMAINS AND VARIANT CL DOMAINS ENGINEERED FOR PREFERENTIAL CHAIN PAIRING AND MULTI-SPECIFIC ANTIBODIES COMPRISING THE SAME
#164MOLECULES WITH ENGINEERED ANTIBODY CONSTANT REGION VARIANTS
#165MULTISPECIFIC ANTIGEN-BINDING PROTEIN AND USE THEREOF
#166POLYPEPTIDE LINKER FOR PREPARING MULTISPECIFIC ANTIBODIES
#167BINDING MOLECULES THAT BIND CD137 AND PD-L1
#168Compositions and methods related to IL27 receptor binding
#169GP130 Binding Molecules and Methods of Use
#170HYPERGLYCOSYLATED BINDING POLYPEPTIDES
#171HETERODIMERIC ANTIBODIES AND ANTIGEN-BINDING FRAGMENT THEREOF
#172Multi-Specific Molecules
#173IL12RB1-BINDING MOLECULES AND METHODS OF USE
#174VISTA ANTIGEN-BINDING MOLECULES
#175MESOTHELIN-TARGETED CD40 AGONISTIC MULTISPECIFIC ANTIBODY CONSTRUCTS FOR THE TREATMENT OF SOLID TUMORS
#176ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#177LAG-3-Binding Molecules and Methods of Use Thereof
#178Bispecific Antibodies with Charge Pairs and Uses Thereof
#179Modified-IgG antibodies that bind transforming growth factor-β1 with high affinity, avidity and specificity
#180HUMANIZED ANTIBODY AGAINST TNFR2 AND USE THEREOF
#181ANTI-SARS-COV-2 ANTIGEN BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF
#182ASSEMBLY OF BISPECIFIC ANTIBODIES
#183AUTOIMMUNE SUPPRESSOR AND APPLICATION THEREOF
#184A BISPECIFIC ANTIBODY TARGETING GPC3 AND CD47
#185ENGINEERED ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF
#186ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF
#187ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#188CONDITIONALLY ACTIVATED ANTIGEN BINDING POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF
#189BISPECIFIC ANTIBODY WHICH BINDS TO CD40 AND EpCAM
#190BISPECIFIC ANTIBODY AND APPLICATION THEREOF
#191Methods for Producing Fabs and IgG Bispecific Antibodies
#192RNA COMPOSITIONS TARGETING CLAUDIN-18.2
#193HEAVY CHAIN ONLY ANTIBODIES TO PDGF
#194Anti-ETEC adhesin protein antibodies and methods of use
#195Natural killer (NK) cell engagers binding to NKp46 and BCMA variants with Fc-engineering
#196ANTIBODIES TO CD40 WITH ENHANCED AGONIST ACTIVITY
#197AGONISTIC ANTI-IL-2R ANTIBODIES AND METHODS OF USE
#198BISPECIFIC BINDING AGENTS BINDING TO CLDN18.2 AND CD3
#199FULL-LENGTH HUMAN IMMUNOGLOBULIN G ANTIBODY LIBRARIES FOR SURFACE DISPLAY AND SECRETION IN SACCHAROMYCES CEREVISIAE
#200MULTISPECIFIC ANTIGEN BINDING PROTEIN
#201ANTI-ROR1 ANTIBODIES AND RELATED BISPECIFIC BINDING PROTEINS
#202ANTI-CD73 ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF
#203METHODS AND COMPOSITIONS
#204ANTI-RSV MONOCLONAL ANTIBODY FORMULATION
#205IL-12 COMPOSITIONS AND METHODS OF USE THEREOF
#206PSEUDOFAB-BASED MULTISPECIFIC BINDING PROTEINS
#207HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
#208BISPECIFIC ANTI-HUMAN A-BETA/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
#209BISPECIFIC ANTIBODY SIMULTANEOUSLY BINDING TO INTERLEUKIN-4 RECEPTOR ALPHA SUBUNIT AND INTERLEUKIN-5 RECEPTOR ALPHA SUBUNIT, AND USE THEREOF
#210PROTEASE CLEAVABLE BISPECIFIC ANTIBODIES AND USES THEREOF
#211PROTEINS BINDING NKG2D, CD16 AND NECTIN4
#212TRISPECIFIC ANTI-CD38, ANTI-CD28, AND ANTI-CD3 BINDING PROTEINS AND METHODS OF USE FOR TREATING VIRAL INFECTION
#213IL-21 polypeptides and targeted constructs
#214BISPECIFIC ANTIBODY
#215METHODS FOR PRODUCING AND/OR ENRICHING RECOMBINANT ANTIGEN-BINDING MOLECULES
#216ANTI-CD28 X ANTI-MSLN ANTIBODIES
#217Antigen binding molecule formats
#218IL-21 polypeptides and targeted constructs
#219Vaccine Compositions and Antibodies For Lyme Disease
#220ANTIBODIES AGAINST SARS-COV-2 AND METHODS OF USING THE SAME
#221METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEX
#222MULTISPECIFIC ANTIBODIES THAT BIND BOTH MAIT AND TUMOR CELLS
#223MULTISPECIFIC BINDING PROTEIN OF IMMUNE CELL ENGAGER, PREPARATION THEREFOR AND APPLICATION THEREOF
#224COMPOSITIONS AND METHODS FOR IN VIVO GENERATION OF CAR EXPRESSING CELLS
#225MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND RELATED METHODS AND USES
#226FUSION PROTEIN COMPRISING IL-12 AND ANTI-CD20 ANTIBODY AND USE THEREOF
#227IL10RB binding molecules and encoding nucleic acids
#228IL27RAlpha binding molecules and methods of use
#229ANTIGEN-BINDING PROTEINS AND RELATED METHODS OF USE
#230ENGINEERED HETERODIMERIC PROTEINS
#231Bispecific antibody
#232Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases
#233IL12 receptor synthetic cytokines and methods of use
#234IFNGR binding synthetic cytokines and methods of use
#235Methods of treating neutorpenia using G-CSF protein complex
#236TRANSGENIC ANIMALS EXPRESSING HEAVY CHAIN ANTIBODIES
#237CH1 DOMAIN VARIANTS ENGINEERED FOR PREFERENTIAL LIGHT CHAIN PAIRING AND MULTISPECIFIC ANTIBODIES COMPRISING THE SAME
#238ANTI-CD28 COMPOSITIONS
#239BINDING DOMAINS AGAINST CANCER-ASSOCIATED MUC1
#240Bispecific Caninized Antibodies for Treating Atopic Dermatitis
#241Agonistic anti-IL-2R antibodies and methods of use
#242ANTIGEN BINDING CONSTRUCTS TARGETING HER2 AND USES THEREOF
#243BISPECIFIC ANTIBODIES COMPRISING A MODIFIED C-TERMINAL CROSSFAB FRAGMENT
#244Trispecific binding proteins, methods, and uses thereof
#245ANTIBODIES BINDING TO GPRC5D
#246ANTI-PD-L1 AND PD-L2 ANTIBODY AND DERIVATIVES AND USE THEREOF
#247BISPECIFIC ANTIBODY AGAINST CLDN18.2 AND CD3
#248Humanized anti-CD3 antibodies, conjugates and uses thereof
#249COMPOSITIONS AND METHODS FOR CORONAVIRUS DETECTION
#250MULTISPECIFIC ANTIBODY AND METHOD FOR PRODUCING SAME
#251Crystallization of Antibodies or Antigen-Binding Fragments
#252CLDN18.2-TARGETING ANTIBODY, BISPECIFIC ANTIBODY AND USE THEREOF
#253HETERODIMERIC PROTEINS WITH FC MUTATIONS
#254METHOD FOR PRODUCING MULTISPECIFIC ANTIGEN-BINDING MOLECULES
#255NEW POLYPEPTIDE COMPLEX
#256POLYPEPTIDE VARIANTS AND USES THEREOF
#257FUSION ANTIBODY FOR PRESENTING ANTIGEN-DERIVED T CELL ANTIGEN EPITOPE OR PEPTIDE CONTAINING SAME ON CELL SURFACE, AND COMPOSITION COMPRISING SAME
#258BISPECIFIC PROTEINS AND METHODS FOR PREPARING SAME
#259Monospecific and bispecific antibodies and antigen binding fragments thereof
#260MULTISPECIFIC ANTIBODIES
#261ANTI-BCMA HEAVY CHAIN-ONLY ANTIBODIES
#262CLAUDIN-6 BINDING MOLECULES AND USES THEREOF
#263Structures for Reducing Antibody-Lipase Binding
#264NOVEL MULTISPECIFIC ANTIBODY FORMAT
#265EXPRESSION OF SEQUENCE-ENGINEERED LAMBDA ANTIBODY LIGHT CHAINS
#266PD-1 binding domains
#267IMMUNOCYTOKINE COMPRISING HETERODYMERIC PROTEIN COMPLEX BASED ON IL-15/IL-15RA
#268SINGLE CHAIN VH AND HEAVY CHAIN ANTIBODIES
#269ANTI-CD3 ANTIBODIES AND METHODS OF USE
#270Bispecific Antibodies with Alternatively Matched Interchain Cysteines and Uses Thereof
#271Multispecific antigen-binding proteins
#272Heterodimeric antibodies that bind CD3 and CD38
#273METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES
#274BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3
#275MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D, AND CD16, AND METHODS OF USE
#276ANTI-TNFR2 ANTIBODIES AND METHODS OF USE
#277MULTISPECIFIC ANTIBODIES
#278SPLIT INTEIN AND PREPARATION METHOD FOR RECOMBINANT POLYPEPTIDE USING THE SAME
#279Bispecific Antibody, Preparation Method Therefor and Application Thereof
#280Modified-IgG antibodies that bind transforming growth factor-BETA1 with high affinity, avidity and specificity
#281Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
#282FUSION OF AN ANTIBODY BINDING CEA AND 4-1BBL
#283COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
#284BISPECIFIC ANTIBODY BINDING TO CD40 AND FAP
#285ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER
#286ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#287Modified antigen binding polypeptide constructs and uses thereof
#288N-terminal scFv multispecific binding molecules
#289CD137- and DLL3-targeting multispecific antigen-binding molecules
#290ANTI-PD-1/LAG3/TIGIT TRISPECIFIC ANTIBODIES AND ANTI-PD-1/LAG3 BICPECIFIC ANTIBODIES
#291FUSION PROTEIN COMPRISING ANTI-MESOTHELIN ANTIBODY, ANTI-CD3 ANTIBODY OR ANTI-EGFR ANTIBODY, BISPECIFIC OR TRISPECIFIC ANTIBODY COMPRISING SAME, AND USES THEREOF
#292PROTEIN COMPLEX BY USE OF A SPECIFIC SITE OF AN IMMUNOGLOBULIN FRAGMENT FOR LINKAGE
#293Antigen binding molecule formats
#294Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
#295BISPECIFIC ANTIBODY WITH DOUBLE HER2 SITES FOR TUMOR IMMUNOTHERAPY
#296ANTIBODIES WITH ENGINEERED CH2 DOMAINS, COMPOSITIONS THEREOF AND METHODS OF USING THE SAME
#297Antigen binding molecule formats
#298Polynucleotides encoding monoclonal antibodies binding to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1) and methods of making thereof
#299ANTI-SIRPalpha MONOCLONAL ANTIBODIES AND USES THEREOF
#300T CELL RECEPTORS AND METHODS OF USE THEREOF